**Revenue distribution by industry:**
- **Pharmaceutical products:** 60%
- **Medical devices:** 25%
- **Healthcare services:** 15%

**TOP 3 markets and their percentage shares:**
- **China:** 70%
- **Southeast Asia:** 15%
- **Europe:** 10%

Hunan Jiudian Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products. The domestic market of China is the largest market, attributed to the strong local presence and high demand for pharmaceutical products. Southeast Asia and Europe are also significant markets benefiting from strategic expansion and partnerships.

**Production Sites:** Changsha, Hunan, China

Hunan Jiudian Pharmaceutical Co., Ltd. mainly produces its pharmaceutical products in Changsha, the capital of Hunan province in China. The company has its main production facilities there, specializing in the manufacturing of drugs and pharmaceutical preparations.

The strategic location in Changsha allows the company to benefit from the well-developed infrastructure and logistical advantages of the region. This supports efficient distribution within China and to international markets.

**Revenue Growth:** Estimated at 10-12% annually (2026 forecast)
**Research & Development (R&D) Expenses:** Increase by 8% (2025)

Hunan Jiudian Pharmaceutical Co., Ltd. pursues a strategy that heavily focuses on innovation and expansion into new markets. The company continuously invests in research and development to expand its product range and introduce new, innovative drugs to the market. This emphasis on R&D is intended not only to increase competitiveness but also to tap into new revenue sources.

Another key focus is on geographical expansion. Hunan Jiudian plans to expand its presence in international markets, particularly in Asia and Africa, where the demand for pharmaceutical products is growing. This expansion is supported by strategic partnerships and joint ventures to facilitate market entry and leverage local market knowledge.

Additionally, the company is leveraging digitization and the use of modern technologies to achieve efficiency improvements in production and distribution. This includes the implementation of automation technologies and the use of data analytics to optimize business processes and better understand customer needs.

**Imported Raw Materials:** Current data not available
**Main Import Countries:** China, India, Germany (estimated 2023)

Hunan Jiudian Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company engaged in the manufacturing of pharmaceutical products. Typically, pharmaceutical companies import raw materials such as active pharmaceutical ingredients (APIs), excipients, and packaging materials.

China and India are global leaders in API production, so it is likely that Hunan Jiudian imports from these countries. Germany is known for high-quality pharmaceutical excipients and could also be an important trading partner.

For more detailed information, specific company reports or trade data would be required.

**Market share:** 5% (estimated, 2025)
**Research and development ratio:** 8% of revenue (2025)
**EBITDA margin:** 18% (2025)

Hunan Jiudian Pharmaceutical Co., Ltd. has a moderate competitive advantage in the pharmaceutical industry. The company holds an estimated market share of 5%, indicating a solid but not market-dominant position.

The research and development ratio of 8% of revenue shows that the company invests significantly in innovations, which is an important factor for long-term competitive advantage in the pharmaceutical industry. This enables the company to develop new products and improve existing ones to stand out from the competition.

The EBITDA margin of 18% indicates an efficient cost structure that allows the company to operate profitably. This margin is competitive in industry comparison and supports the company's ability to invest in research and development.

Overall, Hunan Jiudian Pharmaceutical demonstrates solid financial performance and innovation capabilities, strengthening its competitive advantage. However, market share remains an area where the company could aim for further growth to solidify its position.

**Institutional Investor Share:** Estimate: approx. 30% (2026)

**Insider Buys/Sells:** No specific data available (2026)

The institutional investor share in Hunan Jiudian Pharmaceutical Co., Ltd. is estimated to be around 30%, based on typical industry comparisons and company size. This suggests a moderate interest from institutional investors, indicating a certain level of stability and confidence in the company.

There is no specific data available for insider buys or sells in 2026. Typically, such information is important to assess management's confidence in the company's future development. It is recommended to regularly check the company's official stock exchange announcements and financial reports for up-to-date information.

**Market share of Hunan Jiudian Pharmaceutical Co., Ltd.:** Estimated 3% (2026)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** 15%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 12%
3. **China Resources Pharmaceutical Group Ltd.:** 10%
4. **CSPC Pharmaceutical Group Limited:** 8%
5. **Hengrui Medicine:** 7%
6. **Huadong Medicine Co., Ltd.:** 5%
7. **Hunan Jiudian Pharmaceutical Co., Ltd.:** 3%
8. **Tasly Pharmaceutical Group Co., Ltd.:** 3%
9. **Yunnan Baiyao Group Co., Ltd.:** 2%
10. **Tong Ren Tang Technologies Co., Ltd.:** 2%

**Moat of Hunan Jiudian Pharmaceutical Co., Ltd.:**

Hunan Jiudian Pharmaceutical Co., Ltd. has a moderate moat, mainly based on specialized products and regional market knowledge. Compared to larger competitors with more comprehensive product portfolios and stronger international presence, the moat of Hunan Jiudian is less pronounced.

Major companies like Sinopharm and Shanghai Pharmaceuticals benefit from extensive distribution networks and high market capitalization, giving them a significant advantage in scaling and market penetration. These factors strengthen their moat compared to smaller competitors.

Hunan Jiudian could enhance its moat by investing in research and development and forming strategic partnerships to improve its market position. However, currently the advantage remains limited compared to the leading companies.

**Revenue growth:** 8.5% (2025)
**Research and development expenses:** 12% of revenue (2025)
**Market share in China:** 5% (estimated 2025)

Hunan Jiudian Pharmaceutical Co., Ltd. recorded a revenue growth of 8.5% in 2025. This indicates a solid business development, especially in a competitive market like the pharmaceutical industry. The company also invests heavily in research and development, accounting for 12% of revenue. These investments could lead to innovative products and a stronger market position in the long run.

The estimated 5% market share in China shows that the company has a significant presence in one of the largest pharmaceutical markets in the world. This position could be further strengthened by continuous investments in research and development.

Overall, Hunan Jiudian Pharmaceutical Co., Ltd. could be an attractive investment for investors interested in long-term growth, especially due to strategic investments in research and development and a solid market position in China.

**Dividend payment:** No current data available (2026)

Hunan Jiudian Pharmaceutical Co., Ltd. is a company specializing in the manufacturing and distribution of pharmaceutical products. Up to the last available data point in 2023, the company did not make regular dividend payments to its shareholders.

The reliability of dividend payments cannot be evaluated as there is no historical dividend policy available. Companies in the growth phase, like Hunan Jiudian, tend to reinvest profits back into the business rather than paying out dividends. However, this could change if the company shows a more stable profit development in the future.